Headquarters
France
team size
20 - 49
founded
2010
website
http://www.affilogic.com
funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
Offices
France
HQ address
2 rue de la Houssinière, Nantes, 44800, FRA
Email
inquiries@affilogic.com
description
Affilogic is a privately-owned biotech company specialized in discovery and development of a novel class of protein therapeutics called Nanofitins. They are potent antibody-mimetics, exhibiting high affinity and specificity for capture and targeting of biomolecules. Nanofitins also demonstrate many small molecule-like attributes such as a very small size (7 kDa, around 20 times smaller than a monoclonal antibody), an extreme robustness and a better tissue penetration. Deriving from a naturally hyperstable scaffold, Nanofitins are resistant to temperature and pH, stable to proteases, spontaneously refolding… Being under a single protein format, Nanofitins are produced by simple, scaleable, GMP- compliant bacterial fermentation at very attractive costs or by chemical synthesis.

Affilogic has designed Nanofitins against 40+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (Virus-like Particles, bacteria, whole cells). Nanofitin-based drugs aim at overcoming antibodies limitations and outperforming current targeted therapies by allowing local delivery formulations, single-gene multi-specific molecules and Nanofitin-Drug-Conjugates.

Affilogic is looking for new partners for custom generation of Nanofitins as next generation biopharmaceuticals.

The generation of Nanofitins consists in identifying the best ligands amongst the vast library of variants through in vitro selection. Libraries are screened with many parameters to tune specificity on the target (cross-binding, competition…). This animal-free process is amenable to toxic targets, or non-immunogenic epitopes and usual selection process yields to a number of different monomeric hits with a high affinity down to single-digit picomolar.

NEWS

There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats